PPMD's Blog – February 2013 Archive (5)

Pipeline Update: Drisapersen (GSK2402968) - GSK

GSK recently announced in their Q4 2012 results that the…


Added by PPMD on February 20, 2013 at 12:00pm — No Comments

Advocates in Muscular Dystrophy Community Press Congress for Fast Action on Muscle Disease Research and Treatment

The Muscular Dystrophy Association, Parent Project Muscular Dystrophy and the Foundation to Eradicate Duchenne have called on the U.S. Senate and the U.S. House of Representatives to reauthorize the MD CARE Act of 2001, and to continue federal support for the accelerated pace of research and treatment development for muscular dystrophy. We are urging the public to contact their U.S. Senators and ask them to vote for reauthorization of …


Added by PPMD on February 19, 2013 at 10:30am — No Comments

Summit forms Advisory Board to support development of Duchenne program

Summit recently announced the formation of an Advisory Board to support the scientific and clinical development of its utrophin modulator program for the treatment of Duchenne.

The Board brings together six world-renowned scientists and clinicians with expertise in the field of neuromuscular diseases, and particularly Duchenne.

Included are…


Added by PPMD on February 14, 2013 at 10:00am — No Comments

PPMD Funds Collection and Analysis of Imaging Data from Eteplirsen Study

Parent Project Muscular Dystrophy (PPMD) announced that it has funded $59,000 to Krista Vandenborne, PhD  of the University of Florida in Gainesville to test the ability of magnetic resonance imaging  (MRI) to detect changes in the muscles of  those living with …


Added by PPMD on February 4, 2013 at 8:30am — No Comments

Prosensa Achieves Orphan Drug Status on its Entire Duchenne Portfolio

Leiden, The Netherlands  29 January 2013 – Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced it has achieved orphan drug designation in the EU and the US for all of its compounds for the treatment of Duchenne muscular dystrophy (DMD).


The European Medicines Agency (EMA) assigned orphan drug status to Prosensa’s two preclinical compounds PRO052 and PRO055 and the US Food and…


Added by PPMD on February 1, 2013 at 12:16pm — No Comments

Monthly Archives










Need help using this community site? Visit Ning's Help Page.



© 2022   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service